Tuesday, February 23, 2021
5:00pm PT | 8:00pm ET | 9:00pm AT
International expert: Petros Grivas
Canadian KOL: Kala Sridhar
1. Review recent data on first line strategies for advanced urothelial carcinoma
2. Discuss novel and emerging targets for patients with pre-treated disease
3. Highlight emerging and future clinical trials to answer unmet needs
SERIES SPONSOR: Janssen
Specific Sponsors: Bristol Myers Squibb, EMD Serono Pfizer, Merck
Accredited for Section 1 Credits √
Questions? Contact Tal at the CUA - email@example.com
NOTE: For members who would like this activity recorded in their profile, please use the email that is associated with your CUA membership.
***This webinar is reserved for healthcare professionals and sponsoring companies.
Registration will be vetted before event links are provided to participants.***
Ce programme est disponible en anglais seulement.